Raphael Pharmaceutical (RAPH) Change in Account Payables (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Change in Account Payables of $291000.0 for Q4 2025, up 52.36% sequentially from $191000.0 in Q3 2025, and up 171.85% YoY from $107043.6 in Q4 2024.
Raphael Pharmaceutical (RAPH) Change in Account Payables (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Change in Account Payables for 6 years, with the latest figure at $291000.0 in Q4 2025.
- Quarterly Change in Account Payables rose 171.85% year-over-year to $291000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $818000.0 (up 330.53% YoY) and the FY2025 annual result came in at $818000.0, up 330.53% from the prior year.
- Change in Account Payables grew to $291000.0 in Q4 2025 per RAPH's latest filing, from $191000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $421000.0 in Q3 2023 and troughed at -$405000.0 in Q4 2024.
- A 5-year average of $51850.0 and a median of $14000.0 in 2021 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables tumbled 10300.0% in 2023, then jumped 831.58% in 2025.
- Over 5 years, Change in Account Payables stood at -$127000.0 in 2021, then soared by 53.54% to -$59000.0 in 2022, then sank by 266.1% to -$216000.0 in 2023, then tumbled by 87.5% to -$405000.0 in 2024, then soared by 171.85% to $291000.0 in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered $291000.0, $191000.0, and $278000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 291,000.00 |
| Dec 31, 2025 | 291,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | -405,000.00 |
| Dec 31, 2024 | -405,000.00 |
| Sep 30, 2024 | 249,000.00 |
| Sep 30, 2024 | 249,000.00 |
| Jun 30, 2024 | -38,000.00 |
| Jun 30, 2024 | -38,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Sep 30, 2023 | 421,000.00 |
| Sep 30, 2023 | 421,000.00 |